By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Dendreon Corporation 

3005 First Avenue

Seattle  Washington  98121  U.S.A.
Phone: 206-256-4545 Fax: 206-256-0571



Company News
Troubled Dendreon Corporation (DNDN) Files For Chapter 11 Bankruptcy 11/10/2014 5:56:06 AM
Struggling Dendreon Corporation (DNDN) Plunges After Warning Investors Of Debt Woes 8/13/2014 6:03:14 AM
Flailing Dendreon Corporation (DNDN) Brings In Ex-Johnson & Johnson (JNJ) Exec For Top CEO Post 7/31/2014 6:37:54 AM
Financially Troubled Dendreon Corporation (DNDN) Loses Its CEO 6/9/2014 4:30:01 PM
Dendreon Corporation (DNDN) Release: Treatment With PROVENGE® (Sipuleucel-T) Induces Antigen Spread Associated With Overall Survival Benefits In Advanced Prostate Cancer 5/20/2014 10:18:15 AM
Dendreon Corporation (DNDN) Announces Presentation Of PROVENGE┬« (sipuleucel-T) And DN24-02 Immuno-Oncology Data At The 2014 American Society of Clinical Oncology Annual Meeting 5/15/2014 8:08:39 AM
Dendreon Corporation (DNDN) Announces First Quarter 2014 Results 5/8/2014 9:21:00 AM
Dendreon Corporation (DNDN) To Host Conference Call On May 8 To Announce First Quarter Financial Results 4/29/2014 10:04:28 AM
Dendreon Corporation (DNDN) Release: Immune Responses Enhanced And Sustained When PROVENGE® (Sipuleucel-T) Is Given After Androgen Deprivation Therapy In Biochemically-Recurrent Prostate Cancer 4/11/2014 8:15:28 AM
Dendreon Corporation (DNDN) Announces Plans To Make PROVENGE® Commercially Available In Europe 3/3/2014 8:17:24 AM